Johnson & Johnson: Successfully Strategizing for the Changing Global Business Environment I. Introduction Johnson & Johnson is the world’s largest healthcare company. Founded in the United States in 1886‚ the company has been profitable for 75 straight years and currently operates 250 subsidiary companies in 57 countries. Its products fall into three segments: pharmaceuticals‚ with 39% of total sales; medical devices and diagnostics‚ with 36%;
Premium Generic drug Pharmaceutical industry Medicine
Technique analysis Firstly‚ Johnson & Johnson Pharmaceutical uses focused differentiation technique in marketing its new proprietary medicines (Saylor 5‚ 2013). In 2013‚ it came up with three major medicines: INVOKANA (canagliflozin)‚ IMBRUVICA (ibrutinib) and OLYSIO (simeprevir) (Johnson & Johnson [J&J]‚ 2013). Each medicine has its own focused market: INVOKANA for Type 2 diabetic patients‚ which affects approximately 26 million people in the United States; IMBRUVICA for people with the rare mantle
Premium Blood sugar Blood sugar Health care
Promote on TV and fashion magazine as a new line of cosmetic product + Appeal more to teens and young female adults as “cosmetic” product + Enhance the brand image as more - May encounter resistance from mothers of target audience - May have to raise price → may not be able to meet sales target - May confuse consumers with the identity of J&J (J&J doesn’t carry cosmetic products in the Philippines) 3) Johnson’s Face Powder as Toiletry • Promote as a convenience product that reduces
Premium Cosmetics Marketing
Product Contamination of Johnson & Johnson MAN 3554-1 Workplace Continuity & Contingency Planning – 1 Michelle Alderman Everest College June 8‚ 2014 The company I chose to write about is Johnson & Johnson and its crisis with Tylenol. Back in 1982 for reasons they did not know due to the “acts of a malevolent person or persons‚ presumably unknown‚ replaced Tylenol Extra-Strength capsules with cyanide-laced capsules‚ resealed the packages‚ and deposited them on the shelves of at least a half-dozen
Premium Consumer Consumer protection Johnson & Johnson
Carolyn Kuzmin Johnson & Johnson Case BUS465 September 21‚ 2014 Primary Issues Johnson and Johnson is facing many quality control problems due to the size and spread of the company The hip recall- and a swarm of other product recalls‚ manufacturing lapses and government inquiries They have struggled with owning up to issues and addressing them quickly enough--- so the brand becomes somewhat tainted The business is still growing with another merger on the horizon so something must be done to address
Premium Medicine Management Strategic business unit
1.What factors help to explain why J&J historically had as many as 12 distribution centers in Europe? By placing so many centers in Europe‚ Johnson & Johnson were focused on meeting the specific needs and service expectations of their customers. By having multiple centers strategically located throughout the country‚ the transportation costs remained low and they could meet certain needs of customers‚ like one day shipping‚ 2 day shipping‚ etc. 2.What steps in the logistics/supply chain network
Premium Supply chain management Logistics Supply chain
The $10‚000 investment made into Johnson and Johnson is a good investment to have in your portfolio. This is because of the stable nature of Johnson and Johnson and the growth trend of the company. Based on the JNJ 10-Ks for the last 5 years ended Jan. 1‚ 2012‚ the revenue trend is growing. Revenues have trended favorably from $61‚095 in the year ended Jan. 2007 to $65‚030 in the year ended Jan. 1‚ 2012. The company is also operating efficiently showing the more stable aspect of this investment
Premium Investment Asset Financial ratios
The Johnson & Johnson Tylenol Incident In 1982 Johnson and Johnson‚ the pharmaceutical company that makes Tylenol announced a nationwide recall of Tylenol; 31 million bottles and a loss of 100 million dollars. This recall was secondary to the death of seven people in the Chicago area after using Tylenol. An investigation reveled the poisoning were found to be that of an outside source. The Tylenol was contaminated with cyanide from an outside source. Johnson and Johnson ’s response to the poisonings
Premium Tylenol Johnson & Johnson Pharmacology
Strategic Analysis for the IBM Corporation Outline A. Cover sheet (1 page) B. Table of Contents (1-2 pages) C. Abstract (1 page) D. Introduction (1-3 pages) a. Summary of long term issues b. Summary of short term issues E. Environment (2-3 pages for a & b; 3-4 for c & d) a. Analysis of the Industry b. Analysis of the stakeholders c. SWOT situational analysis d. Analysis and identification of the organizational goals F. Analyses (4-4 pages for a & b) a. Five Force Analysis of resources
Premium Term Time
Paper 1 EXTERAL ANALYSIS Macroenvironmental Analysis: • Economic: Globalization of the pharmaceutical industry is an exciting opportunity to have research and development done at cheaper prices in other countries. However‚ this could be a double edged sword for companies because it is easy for other countries‚ such as India‚ to produce generic versions of the drug in bulk. • Technological: Profitability is determined mainly by the ability to discover new drugs. Technology is at the forefront
Premium Johnson & Johnson